Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme
Abstract Background Metastatic uveal melanoma (mUM) carries a poor prognosis, with low response rates to checkpoint inhibitors. The phase III first-line IMCgp100-202 trial established tebentafusp, a bi-specific T cell engager, as the first treatment to demonstrate a survival benefit in mUM. Here, we report retrospectiv...